Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth
January 03 2024 - 4:05PM
Business Wire
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a
leading provider of modeling and simulation software and services
for pharmaceutical safety and efficacy, today announced the
following leadership changes effective January 3, 2024.
“We are excited to announce key strategic appointments that will
advance our objective to seamlessly and organically align with our
clients’ needs,” said Shawn O’Connor, Chief Executive Officer. “We
have a deep bench of talent at Simulations Plus, and I am delighted
to recognize the excellent leadership and accomplishments that each
person has demonstrated. This team has a wide range of experience,
proven execution and a shared vision that will strengthen our
ability to realize our strategic growth initiatives.”
Will Frederick, currently Chief Financial Officer,
assumes the additional role of Chief Operating Officer in
recognition of his operational leadership. Mr. Frederick has served
as Chief Financial Officer since joining Simulations Plus in
December 2020.
Dan Szot joins Simulations Plus as Chief Revenue Officer.
In this new role, Mr. Szot oversees the sales and marketing teams
to identify collaborative cross-selling opportunities and enhance
productivity. Mr. Szot was previously at Dassault Systemes where he
served as Global Vice President of Sales and Field Operations for
the BIOVIA brand. In his over 20 years in the industry, Mr. Szot
has had broad experience across all phases of drug development in
large organizations in enterprise sales, research discovery, and
clinical applications. Mr. Szot reports to Shawn O’Connor, Chief
Executive Officer.
Josh Fohey transitions from Vice President of Business
Development to Senior Vice President, Operations. In this key
operational role, Mr. Fohey will leverage his customer insights to
provide leadership across all business units supporting
client-focused services operations, product operations, and quality
management. Mr. Fohey joined Simulations Plus in 2019 as Director
of Operations and was promoted to Vice President, Operations in
2020. Prior to joining Simulations Plus, he had several
operational, scientific, and business development roles during his
14 years at Covance. In his new role, Mr. Fohey reports to Will
Frederick, Chief Financial Officer and Chief Operating Officer.
Sandra Suarez-Sharp, Ph.D., currently Vice President,
Regulatory Affairs, is promoted to President, Regulatory
Strategies. Dr. Suarez-Sharp joined Simulations Plus over three
years ago and has been instrumental in initiating the company’s
regulatory support to clients. Prior to joining Simulations Plus,
Dr. Suarez-Sharp had a long and successful career at the Food and
Drug Administration including roles in biopharmaceutics,
bioequivalence, and clinical pharmacology. In her new role, she is
responsible for expanding Simulations Plus’s Regulatory Strategies
business unit, a fast-growing component of the company’s overall
service offering that is critical to assisting clients in deploying
Simulations Plus software and services for regulatory success. Dr.
Suarez-Sharp reports to CEO Shawn O’Connor.
About Simulations Plus
Serving clients worldwide for more than 25 years, Simulations
Plus is a leading provider in the biosimulation market providing
software and consulting services supporting drug discovery,
development, research, and regulatory submissions. We offer
solutions that bridge artificial intelligence (AI)/machine
learning, physiologically based pharmacokinetics, quantitative
systems pharmacology/toxicology, and population PK/PD modeling
approaches. Our technology is licensed and applied by major
pharmaceutical, biotechnology, and regulatory agencies worldwide.
For more information, visit our website at
www.simulations-plus.com. Follow us on LinkedIn | Twitter |
YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our ESG
website.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to successfully integrate Immunetrics into
our business, our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103293586/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Tamara Gonzalez
310-622-8234 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2024 to May 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From May 2023 to May 2024